{"nctId":"NCT02554383","briefTitle":"Efficacy of Antibiotics in Children With Acute Sinusitis: Which Subgroups Benefit?","startDateStruct":{"date":"2016-02","type":"ACTUAL"},"conditions":["Sinusitis","Respiratory Tract Infections"],"count":515,"armGroups":[{"label":"Treatment A","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Amoxicillin-clavulanate"]},{"label":"Treatment B","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Amoxicillin-clavulanate","otherNames":["Augmentin-Extra strength"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Meets criteria for \"persistent\" or \"worsening\" presentations of sinusitis\n* Baseline score ≥9 on the Pediatric Rhinosinusitis Symptom Scale\n\nExclusion Criteria:\n\n* Severe presentation (≥3 days of colored nasal discharge and fever ≥39°C\n* Asthma/allergic rhinitis explains symptoms\n* Allergy to amoxicillin-clavulanate\n* Immotile cilia syndrome\n* Cystic fibrosis\n* Immunodeficiency\n* Parental inability to read/write English or Spanish\n* Other concurrent infection (e.g., pneumonia, acute otitis media, streptococcal pharyngitis)\n* Systemic toxicity\n* Wheezing on exam\n* Antibiotic use within 15 days","healthyVolunteers":false,"sex":"ALL","minimumAge":"2 Years","maximumAge":"11 Years","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"The Mean Pediatric Rhinosinusitis Symptom Scale (PRSS) Score Over the First 10 Days of Follow-up According to the Presence of Pathogens in the Nasopharynx at Enrollment","description":"The Pediatric Rhinosinusitis Symptom Scale (PRSS) is a 8 item scale assessing symptoms of sinusitis. Parents are asked how their child has been doing over the last 24 hours by rating each of 8 symptoms - stuffy nose, runny nose, daytime cough, tiredness, irritability, trouble breathing through the nose, nighttime cough \\& trouble sleeping - as none, almost none, a little, some, a lot \\& an extreme amount with respective scores of 0, 1, 2, 3, 4 \\& 5. The 8 ratings were summed to obtain a PRSS score. Scores ranged from 0-40. Higher scores indicate greater severity. The parent completed the scale on Day 1 (enrollment) \\& electronically on diaries evenings Days 2-11. Pathogens cultured were Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17.3","spread":"7.8"},{"groupId":"OG001","value":"18.6","spread":"7.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.9","spread":"7.7"},{"groupId":"OG001","value":"16.6","spread":"7.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.8","spread":"7.9"},{"groupId":"OG001","value":"13.9","spread":"7.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.1","spread":"7.6"},{"groupId":"OG001","value":"12.0","spread":"7.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.5","spread":"7.1"},{"groupId":"OG001","value":"10.9","spread":"6.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.3","spread":"6.7"},{"groupId":"OG001","value":"8.9","spread":"6.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.4","spread":"6.7"},{"groupId":"OG001","value":"8.3","spread":"6.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.9","spread":"5.8"},{"groupId":"OG001","value":"7.4","spread":"6.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.2","spread":"5.4"},{"groupId":"OG001","value":"6.0","spread":"5.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.7","spread":"5.1"},{"groupId":"OG001","value":"5.8","spread":"6.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19.5","spread":"7.3"},{"groupId":"OG001","value":"18.7","spread":"7.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.5","spread":"8.1"},{"groupId":"OG001","value":"15.5","spread":"7.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.9","spread":"7.4"},{"groupId":"OG001","value":"12.5","spread":"6.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.3","spread":"7.4"},{"groupId":"OG001","value":"10.5","spread":"6.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.1","spread":"7.1"},{"groupId":"OG001","value":"9.4","spread":"7.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.9","spread":"6.5"},{"groupId":"OG001","value":"8.3","spread":"6.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.2","spread":"6.4"},{"groupId":"OG001","value":"7.4","spread":"6.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.4","spread":"6.1"},{"groupId":"OG001","value":"6.3","spread":"6.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.9","spread":"5.9"},{"groupId":"OG001","value":"5.5","spread":"6.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.1","spread":"5.5"},{"groupId":"OG001","value":"4.1","spread":"5.3"}]}]}]},{"type":"PRIMARY","title":"The Mean Pediatric Rhinosinusitis Symptom Scale (PRSS) Score Over the First 10 Days of Follow-up According to the Presence of Colored Nasal Discharge at Enrollment","description":"The Pediatric Rhinosinusitis Symptom Scale (PRSS) is a 8 item scale assessing symptoms of sinusitis. Parents are asked how their child has been doing over the last 24 hours by rating each of 8 symptoms - stuffy nose, runny nose, daytime cough, tiredness, irritability, trouble breathing through the nose, nighttime cough \\& trouble sleeping - as none, almost none, a little, some, a lot \\& an extreme amount with respective scores of 0, 1, 2, 3, 4 \\& 5. The 8 ratings were summed to obtain a PRSS score. Scores ranged from 0-40. Higher scores indicate greater severity. The parent completed the scale on Day 1 (enrollment) \\& electronically on diaries evenings Days 2-11. Nasal discharge, either yellow or green, was considered colored.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18.6","spread":"7.9"},{"groupId":"OG001","value":"19.0","spread":"7.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.8","spread":"8.3"},{"groupId":"OG001","value":"16.6","spread":"7.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.1","spread":"8.1"},{"groupId":"OG001","value":"13.7","spread":"7.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.8","spread":"7.8"},{"groupId":"OG001","value":"11.3","spread":"6.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.6","spread":"7.1"},{"groupId":"OG001","value":"10.5","spread":"6.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.4","spread":"6.8"},{"groupId":"OG001","value":"8.8","spread":"6.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.4","spread":"6.4"},{"groupId":"OG001","value":"8.2","spread":"7.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.1","spread":"6.1"},{"groupId":"OG001","value":"7.0","spread":"6.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.4","spread":"5.5"},{"groupId":"OG001","value":"5.7","spread":"5.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.7","spread":"5.2"},{"groupId":"OG001","value":"5.2","spread":"5.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.4","spread":"7.1"},{"groupId":"OG001","value":"17.6","spread":"8.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.3","spread":"6.8"},{"groupId":"OG001","value":"15.6","spread":"7.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.1","spread":"7.0"},{"groupId":"OG001","value":"12.9","spread":"8.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.0","spread":"6.8"},{"groupId":"OG001","value":"12.1","spread":"7.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.8","spread":"7.1"},{"groupId":"OG001","value":"10.5","spread":"7.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.7","spread":"6.3"},{"groupId":"OG001","value":"8.8","spread":"6.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.1","spread":"6.9"},{"groupId":"OG001","value":"7.7","spread":"6.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.9","spread":"5.5"},{"groupId":"OG001","value":"7.3","spread":"6.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.5","spread":"5.6"},{"groupId":"OG001","value":"6.2","spread":"6.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.0","spread":"5.2"},{"groupId":"OG001","value":"5.7","spread":"6.9"}]}]}]},{"type":"SECONDARY","title":"The Distribution of Children Experiencing Treatment Failure (TF)","description":"The Pediatric Rhinosinusitis Symptom Scale (PRSS) is a 8 item scale assessing symptoms of sinusitis. Parents are asked how their child has been doing over the last 24 hours by rating each of 8 symptoms - stuffy nose, runny nose, daytime cough, tiredness, irritability, trouble breathing through the nose, nighttime cough \\& trouble sleeping - as none, almost none, a little, some, a lot \\& an extreme amount with respective scores of 0, 1, 2, 3, 4 \\& 5. The 8 ratings were summed to obtain a PRSS score. Scores ranged from 0-40. Higher scores indicate greater severity. The parent completed the scale on Day 1 (enrollment), electronically evenings Days 2-11 \\& at the follow-up visit. If, compared to the Day 1 score, there was \\>20% increase at any time, decrease \\<2 on Day 3, \\<20% decrease on Day 4, \\<20% decrease on 2 consecutive occasions Days 5-11 or \\<50% decrease at follow-up, then criterion for treatment failure (TF) was met. Multiple imputation was used when data was insufficient to assess TF.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"76","spread":null},{"groupId":"OG001","value":"111","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"178","spread":null},{"groupId":"OG001","value":"145","spread":null}]}]}]},{"type":"SECONDARY","title":"The Distribution of Children Developing Acute Otitis Media (AOM) Over the First 10 Days of Follow-up","description":"AOM is an infection of the middle ear marked by acute symptoms and a bulging tympanic membrane. Its diagnosis coincided with receipt of a systemic antibiotic. Systemic antibiotics include Amoxicillin, Amoxicillin-clavulanate, Azithromycin, Bacillin L-A, Cefdinir, Clindamycin, Doxycycline, Levofloxacin, Ofloxacin \\& Sulfamethoxazole-Trimethoprim. Start and stop dates were recorded.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"251","spread":null},{"groupId":"OG001","value":"248","spread":null}]}]}]},{"type":"SECONDARY","title":"The Distribution of Children Receiving a Systemic Antibiotic Over the First 10 Days of Follow-up","description":"Systemic antibiotics include Amoxicillin, Amoxicillin-clavulanate, Azithromycin, Bacillin L-A, Cefdinir, Clindamycin, Doxycycline, Levofloxacin, Ofloxacin \\& Sulfamethoxazole-Trimethoprim. Start and stop dates were recorded. The antibiotic received is exclusive of the study product assigned at enrollment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34","spread":null},{"groupId":"OG001","value":"66","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"217","spread":null},{"groupId":"OG001","value":"190","spread":null}]}]}]},{"type":"SECONDARY","title":"The Distribution of Children for Whom Diarrhea or Generalized Rash Was Reported","description":"The monitoring of adverse events (AEs), i.e. diarrhea or generalized rash, began on Day 1 (enrollment) and continued through Day 23 (the follow-up visit). Diarrhea was the occurrence of 3 or more watery stools on one day or 2 watery stools on each of 2 consecutive days. Parents recorded in daily diaries, Days 1-11, information regarding the occurrence of diarrhea. Additionally, parents were asked at the follow-up visit if their child had diarrhea while on study product.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31","spread":null},{"groupId":"OG001","value":"13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"223","spread":null},{"groupId":"OG001","value":"243","spread":null}]}]}]},{"type":"SECONDARY","title":"The Distribution of Children Compliant With Study Medication","description":"Compliance, expressed as a percentage, is the total number of doses taken divided by the total number of expected doses. The child is considered compliant if he/she has received at least 70% of the study medication. The parent completed diaries evenings Days 2-11. The diaries included yes/no questions - (1) did your child take the study medication last night and (2) did your child take the study medication this morning? The total number of doses taken was calculated based on the responses to question (1), and accounted for the dose dispensed at enrollment when enrollment was 1pm or earlier on Day 1. The total of expected doses was determined from the responses to questions (1) and (2), and accounted for scenarios in which the child was taken off the study medication by the clinician. In some cases, due to incomplete diaries the information was insufficient to declare a child either compliant or not compliant.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"212","spread":null},{"groupId":"OG001","value":"221","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"13","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"The Distribution of Children With a Nonsusceptible Pathogen at the Follow-up Visit","description":"The nonsusceptible pathogens considered are penicillin-intermediate and penicillin-resistant Streptococcus pneumoniae (SPN) and ß-lactamase-positive Haemophilus influenzae (NTHi). Susceptibility to penicillin was defined as follows: susceptible as a minimum inhibitory concentration (MIC) of \\<=0.06 μg/mL; intermediate as an MIC of greater than 0.06 to less than 2 μg/mL; and resistant as an MIC of \\>=2 μg/mL. A nasopharyngeal specimen for bacterial culture was obtained at the time of the follow-up visit, occurring between study days 11 and 23.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"18","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"129","spread":null},{"groupId":"OG001","value":"134","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":254},"commonTop":["Diarrhea"]}}}